Molecular Predictors of Response to a Humanized Anti-Insulin-Like Growth Factor-I Receptor Monoclonal Antibody in Breast and Colorectal Cancer

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-09-0381
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Akt/mTOR Counteract the Antitumor Activities of Cixutumumab, an Anti-Insulin-Like Growth Factor I Receptor Monoclonal Antibody

Molecular Cancer Therapeutics
Cancer ResearchOncology
2011English

Apoptosis Induced by an Anti-Epidermal Growth Factor Receptor Monoclonal Antibody in a Human Colorectal Carcinoma Cell Line and Its Delay by Insulin.

Journal of Clinical Investigation
Medicine
1995English

Phase 1 Pharmacokinetic Study of MK-0646 (Dalotuzumab), an Anti-Insulin-Like Growth Factor-1 Receptor Monoclonal Antibody, in Combination With Cetuximab and Irinotecan in Japanese Patients With Advanced Colorectal Cancer

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2013English

Insulin-Like Growth Factor Receptor Type I as a Target for Cancer Therapy

Frontiers in Bioscience - Scholar
ImmunologyMolecular BiologyBiochemistryMicrobiology MedicineGenetics
2013English

A Phase I Study of Farletuzumab, a Humanized Anti-Folate Receptor Α Monoclonal Antibody, in Patients With Solid Tumors

Investigational New Drugs
OncologyPharmacology
2014English

Correlation of Insulin-Like Growth Factor 1 Receptor Expression With Different Molecular Subtypes of Breast Cancer in the UAE

Anticancer Research
MedicineCancer ResearchOncology
2020English

Differential Roles of the Insulin and Insulin-Like Growth Factor-I (IGF-I) Receptors in Response to Insulin and IGF-I.

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2016English

Insulin-Like Growth Factor-I and Prostate Cancer: A Meta-Analysis

British Journal of Cancer
Cancer ResearchOncology
2001English

Phase I Study of the Anti Insulin-Like Growth Factor 1 Receptor (IGF-1R) Monoclonal Antibody, AVE1642, as Single Agent and in Combination With Bortezomib in Patients With Relapsed Multiple Myeloma

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy